|Bid||295.270 x 100|
|Ask||295.390 x 100|
|Day's Range||285.020 - 296.950|
|52 Week Range||244.280 - 333.650|
|PE Ratio (TTM)||18.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yesterday, shares of Biogen (BIIB) finished lower on the day despite the fact that it reported Street-beating earnings. Today, they're gaining what they should have yesterday after Goldman Sachs upgraded ...
Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB ) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn ...
Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.